Description: Codex DNA is a synthetic biology company focused on enabling researchers to rapidly, accurately and reproducibly build or “write” high-quality synthetic DNA and mRNA that is ready to use in many downstream synthetic biology enabled markets. Codex DNA’s synthetic biology solution addresses the bottlenecks across the multi-step process of building DNA and mRNA, as well as the significant limitations of existing solutions that prevent the rapid building of virtually error-free DNA and mRNA at a useable scale. A key part of Codex DNA’s solution is the BioXp™ system, an end-to-end automated workstation that fits on the benchtop and is broadly accessible due to its ease-of-use and hands-free automation. Codex DNA believes the BioXp™ system can democratize synthetic biology by simplifying the process of building DNA and mRNA, thereby accelerating the discovery, development, and production of novel high-value products, including antibody-based biologics, mRNA-based vaccines and therapeutics and precision medicines.
Home Page: telesisbio.com
TBIO Technical Analysis
10431 Wateridge Circle
San Diego,
CA
92121-2993
United States
Phone:
858 228 4115
Officers
| Name | Title |
|---|---|
| Mr. Eric Esser | President, CEO, COO & Chairman |
| Mr. William J. Kullback | Chief Financial Officer |
| Mr. Daniel G. Gibson Ph.D. | Chief Technology Officer |
| Ms. Jen Carroll | Vice President of Investor Relations |
| Mr. Decky Goodrich M.B.A. | Senior Vice President of Corporate Development |
| Richard Lepke | Director of Investor Relations |
Exchange: PINK
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Health Care Equipment & Services |
| GIC Industry: | Health Care Equipment & Supplies |
| GIC Sub-Industry: | Health Care Equipment |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.1076 |
| Price-to-Sales TTM: | 0.0523 |
| IPO Date: | 2021-06-18 |
| Fiscal Year End: | December |
| Full Time Employees: | 137 |